Anu Sharma

Anu Sharma

Auto-generated profile, based on publicly available information

Anu Sharma

College of Medicine, University of Florida, Gainesville, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Current Opinion in Endocrinology, Diabetes and Obesity
Verified
Journal Article
Closed access
ASAnu Sharma
Anu Sharma
AVAdrian Vella
Adrian Vella
Purpose of review: Impairment of glucose metabolism is commonly encountered in Cushing's syndrome. It is the source of significant morbidity and mortality even after successful treatment of Cushing's. This review is to understand the recent advances in understanding the pathophysiology of diabetes mellitus from excess cortisol. Recent findings: In-vitro studies have led to significant advancement in understanding the molecular effects of cortisol on glucose metabolism. Some of these findings have been translated with human data. There is marked reduction in insulin action and glucose disposal with a concomitant, insufficient increase in insulin secretion. Cortisol has a varied effect on adipose tissue, with increased lipolysis in subcutaneous adipose tissue in the extremities, and increased lipogenesis in visceral and subcutaneous truncal adipose tissue. Summary: Cushing's syndrome results in marked impairment in insulin action and glucose disposal resulting in hyperglycemia. Further studies are required to understand the effect on incretin secretion and action, gastric emptying, and its varied effect on adipose tissue.

9 November 2020 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
YLYu Kuei Lin
Yu Kuei Lin
DGDanielle Groat
Danielle Groat
OCOwen Chan
Owen Chan
MHMan Hung
Man Hung
ASAnu Sharma
Anu Sharma
SFSimon J. Fisher
Simon J. Fisher
Background: Continuous glucose monitoring (CGM) systems help reduce hypoglycemia in patients with type 1 diabetes (T1D). It remains unclear whether T1D patients with impaired awareness of hypoglycemia (IAH) continue to develop more hypoglycemia than those with normal hypoglycemia awareness (NA) despite CGM use. Materials and Methods: For this cross-sectional observational study, 99 T1D patients using real-time CGMs for ≥86% of time were recruited. Fifty and 49 patients were found to have NA and IAH (based on the Clarke questionnaire), respectively. Two-week CGM hypoglycemia data were collected. Results: IAH was associated with greater percentages of CGM values <70 and <54 mg/dL ( P = 0.012, P = 0.004) compared to NA. Clarke scores correlated positively with the percentage of CGM values <70 and <54 mg/dL ( P = 0.013, P = 0.004). IAH was also related to more events with glucose <70 and <54 mg/dL determined either with at ≥1 time point ( P = 0.048, P = 0.003) or lasting ≥20 min ( P = 0.016, P = 0.004). IAH patients presented with more day-time events with glucose <54 mg/dL ( P = 0.015), nocturnal events with glucose levels <70 and <54 mg/dL ( P = 0.009, P = 0.007) and longer day-time event duration with glucose levels <70 and <54 mg/dL ( P < 0.001, P = 0.006), respectively. Conclusions: T1D patients with IAH continue to experience more hypoglycemia despite dedicated CGM use.

24 September 2024 in Obesity
Verified
Journal Article
Closed access
ASAnu Sharma
Anu Sharma
ELEddison Godinez Leiva
Eddison Godinez Leiva
SKSrilaxmi Kalavalapalli
Srilaxmi Kalavalapalli
RLRomina Lomonaco
Romina Lomonaco
SMStephen A. Marangi
Stephen A. Marangi
KCKenneth Cusi
Kenneth Cusi

20 June 2014 in Environmental Monitoring and Assessment
Verified
Journal Article
Closed access
PDF file
AAAnubha Agrawal
Anubha Agrawal
ASAnu Rani Sharma
Anu Rani Sharma
STShresth Tayal
Shresth Tayal

2 September 2022 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
ASAnu Sharma
Anu Sharma
BKBenjamin Krick
Benjamin Krick
YLYing Li
Ying Li
SSScott A Summers
Scott A Summers
MPMary C Playdon
Mary C Playdon
CWCorrine Welt
Corrine Welt
Context Polycystic ovarian syndrome (PCOS) is a complex disorder in which metabolic abnormalities are associated with reproductive dysfunction. Women with PCOS have increased ceramide concentrations. Previous studies demonstrated that treating metabolic abnormalities of PCOS with metformin improved glucose effectiveness after 12 weeks. Objective We evaluated whether, in women with PCOS, lower baseline ceramide, diacylglycerol (DAG), and triacylglycerol (TAG) concentrations were associated with improved metabolic response to metformin. Methods Women (n = 29), aged 29 ± 5 years and diagnosed with PCOS by the NIH criteria underwent an intravenous glucose tolerance test (IVGTT) before and after 12-week treatment with metformin (1500 mg per day). Metabolic responders were defined by improved glucose effectiveness, specifically, the ability of glucose to stimulate uptake and suppress production, after metformin treatment. Results Twelve weeks of metformin resulted in weight loss (−1.7 ± 2.6 kg, P < 0.01) and a reduction in BMI (−0.6 ± 0.9 kg/m2, P < 0.01) with no change in HbA1c. The concentrations of Cer(d18:1/22:0), Cer(d18:1/24:0), total ceramides, total Cer(d16:0), total Cer(d18:2), DAG, dihydrosphingomyelin (DHSM), and TAG decreased after metformin treatment (P < 0.05). Baseline total Cer(d16:0) concentration <204.1 pmol/mL was 82% sensitive (AUC 0.72, P = 0.03) and total DHSM concentration <32237 pmol/mL was 100% specific (AUC 0.73, P = 0.03) in predicting improved metabolic response to metformin, as measured by IVGTT. Conclusion Lower total Cer(16:0) and DHSM concentrations are associated with a beneficial metabolic response to metformin in women with PCOS. Based on the known association between higher ceramide levels and type 2 diabetes, the data suggest that metformin improves metabolic parameters in women with mild metabolic derangements.

11 February 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ARAndrea Ortiz Rocha
Andrea Ortiz Rocha
SKSrilaxmi Kalavalapalli
Srilaxmi Kalavalapalli
ELEddison Godinez Leiva
Eddison Godinez Leiva
DBDiana Barb
Diana Barb
FBFernando Bril
Fernando Bril
KCKenneth Cusi
Kenneth Cusi
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.